Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- PMDA Unveils New International Strategy
June 30, 2015
- MHLW Global Strategy Aims at Regulatory Shortcut for Japan-OK’ed Drugs
June 29, 2015
- Drug Pricing Tomorrow: MHLW’s Jo Says Price-Maintenance Premium Crucial as Post-Launch Reward for Innovation
June 29, 2015
- MHLW Approves Additional Indications for Radicut and Other Products
June 29, 2015
- 8 Members Exit Pharmaceutical Affairs Council
June 26, 2015
- LDP OKs Economic, Fiscal Policy Guidelines, but Wording on Reference Pricing Could Change
June 26, 2015
- Problems at Kaketsuken Remained Undetected Despite 21 On-Site Inspections over 10-Year Period: PMDA
June 26, 2015
- Univ. of Tokyo Prof. Tanabe Elected as Chuikyo Chairman
June 25, 2015
- HTAs Likely to Be Used for Re-Pricing of Listed Medicines
June 25, 2015
- AMED Initiates “Middle Molecule Drug Discovery” Project; Aims to Out-License Lead Compounds to Drug Makers
June 25, 2015
- Panel Begins Discussions on Revising Basic Guidelines for Measures against Hepatitis
June 25, 2015
- Drug Pricing Tomorrow: Ex-Chuikyo Chair Urges Pharma to Look at How to Refine Premium, Not Permanent Introduction
June 25, 2015
- Kaketsuken Likely to Face Administrative Penalty over GMP Violation
June 24, 2015
- LDP Begins Intraparty Deliberations on Economic, Fiscal Blueprint
June 24, 2015
- PMDA Beats Its Targets for Overall Review Time in FY2014
June 24, 2015
- Draft Growth Strategy Embraces Clinical Development Infrastructure, Drops Numerical Target for Sakigake System
June 23, 2015
- 80% Generic Share “at Early Date,” Essential Drug Supplies Join Draft Fiscal Policy Blueprint
June 23, 2015
- PMDA, AMED Plan to Enter Partnership Agreement; Share Information to Promote Commercialization of Seeds
June 23, 2015
- Editor’s Pick: Five Healthcare News Headlines for June 8 - June 21
June 22, 2015
- AMED’s Screening Consortium “Won’t Harm Companies”: Official
June 22, 2015
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…